UBS Group Issues Positive Forecast for MiniMed Group (NASDAQ:MMED) Stock Price

Key Points

• UBS Group raised its MiniMed Group price target to $28 from $25 and maintained a “buy” rating, implying 17.94% upside from the prior close.
• Analyst sentiment is broadly positive: 13 analysts rate the stock “buy,” two “hold,” and one “sell,” resulting in a consensus “Moderate Buy” rating and average target price of $23.08.
• MiniMed shares rose 5.9% to $23.74, while institutional ownership increased as BlackRock and other investors added significant positions; however, the company’s latest quarterly EPS loss missed estimates despite 15.6% year-over-year revenue growth.

MiniMed Group (NASDAQ:MMED - Get Free Report) had its price objective hoisted by equities researchers at UBS Group from $25.00 to $28.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a "buy" rating on the stock. UBS Group's target price would indicate a potential upside of 17.94% from the stock's previous close.

A number of other equities analysts have also recently commented on MMED. Bank of America lifted their price target on shares of MiniMed Group from $24.00 to $28.00 and gave the stock a "buy" rating in a research note on Wednesday. Weiss Ratings upgraded shares of MiniMed Group from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, July 20th. Piper Sandler restated a "neutral" rating and issued a $16.00 target price on shares of MiniMed Group in a research note on Thursday, June 4th. Mizuho lifted their price target on shares of MiniMed Group from $21.00 to $26.00 and gave the company an "outperform" rating in a research note on Wednesday. Finally, Wells Fargo & Company dropped their price objective on MiniMed Group from $26.00 to $22.00 and set an "overweight" rating on the stock in a research note on Thursday, June 4th. Thirteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $23.08.

MiniMed Group Stock Up 5.9%

Shares of NASDAQ:MMED opened at $23.74 on Wednesday. The business has a fifty day simple moving average of $17.65. MiniMed Group has a 52 week low of $10.65 and a 52 week high of $22.74. The stock has a market cap of $6.68 billion and a PE ratio of -34.48.

MiniMed Group (NASDAQ:MMED - Get Free Report) last released its quarterly earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.46). The company had revenue of $837.00 million during the quarter. The company's revenue was up 15.6% on a year-over-year basis. On average, equities research analysts forecast that MiniMed Group will post 0.66 earnings per share for the current year.

Institutional Investors Weigh In On MiniMed Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MMED. BlackRock Inc. raised its stake in MiniMed Group by 7,527.5% in the 2nd quarter. BlackRock Inc. now owns 1,996,489 shares of the company's stock worth $29,848,000 after acquiring an additional 1,970,314 shares during the last quarter. J. Goldman & Co LP purchased a new stake in MiniMed Group in the second quarter valued at approximately $12,412,000. Readystate Asset Management LP acquired a new position in MiniMed Group in the 2nd quarter worth approximately $4,400,000. Bank of America Corp DE raised its position in MiniMed Group by 377.0% during the 2nd quarter. Bank of America Corp DE now owns 238,819 shares of the company's stock worth $3,570,000 after buying an additional 188,756 shares during the last quarter. Finally, Freestone Grove Partners LP acquired a new stake in MiniMed Group during the 2nd quarter valued at approximately $1,745,000.

Key Headlines Impacting MiniMed Group

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: MiniMed reported fiscal Q1 net sales of $843 million, up 17% year over year, while organic U.S. revenue growth accelerated to 13%. International sales also grew strongly, supporting management’s decision to raise its fiscal 2027 organic revenue-growth guidance. MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration
• Positive Sentiment: Fiscal Q1 earnings per share of approximately $0 exceeded analyst expectations, contributing to the favorable initial market reaction. Earnings Flash: MiniMed Posts Fiscal Q1 EPS
• Positive Sentiment: MiniMed highlighted progress across its product pipeline, including an FDA submission for MiniMed Fit, a CE Mark for MiniMed Flex, completion of enrollment in the Vivera pivotal trial and IDE approval for a next-generation extended-wear sensor. MiniMed Group Q1 2027 Deep Dive
• Positive Sentiment: Analyst sentiment strengthened after the results. Mizuho raised its target from $21 to $26 with an “outperform” rating; Bank of America lifted its target from $24 to $28 with a “buy” rating; and BTIG also raised its target to $28 and maintained a “buy” rating.
• Negative Sentiment: The reported brokerage consensus target of $21.62 remains below the stock’s recent trading level, indicating that not all analysts have fully reflected the latest operating momentum in their estimates. MiniMed Receives Consensus Target Price from Brokerages

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source